Figure 2.
Distribution of patients with AML based on their cytogenetic and molecular profile. (A) Distribution of secondary AML (n = 397 AML with MDS-related categories), based on the presence of MDS-related cytogenetic abnormalities. Each category was further stratified according to the hierarchical ICC classification system, shown in the outer circle (AML with TP53 mutation, AML with myelodysplasia-related gene mutations, and AML with myelodysplasia-related cytogenetic abnormalities: gray shades). (B) Frequency of ICC diagnostic subcategories in patients with AML with NK (n = 452).

Distribution of patients with AML based on their cytogenetic and molecular profile. (A) Distribution of secondary AML (n = 397 AML with MDS-related categories), based on the presence of MDS-related cytogenetic abnormalities. Each category was further stratified according to the hierarchical ICC classification system, shown in the outer circle (AML with TP53 mutation, AML with myelodysplasia-related gene mutations, and AML with myelodysplasia-related cytogenetic abnormalities: gray shades). (B) Frequency of ICC diagnostic subcategories in patients with AML with NK (n = 452).

Close Modal

or Create an Account

Close Modal
Close Modal